SAINT PETERSBURG, FL, Nov. 12, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Apotheca Biosciences (OTC PINK: PCFP), a developer of cutting-edge medical products, nutraceuticals, drug formulations and cannabis delivery technologies for the healthcare and consumer care industry is pleased to announce the Company's plans to uplist to the OTCQB market within the next few weeks. The application process will not guarantee acceptance of Company’s application by OTCMARKETS from the PINKS to OTCQB.
The Company believes that the move to the OTCQB will provide enhanced investor benefits including higher reporting standards, greater access to analyst coverage and news services, and more comprehensive compliance requirements. The OTCQB is considered by the Securities and Exchange Commission (SEC) as an "established public market" for determining the public market price when registering securities for resale with the SEC. The OTC Pink is not considered as such and most broker dealers will not trade or recommend OTC Pink stocks. Because the OTCQB dramatically increases transparency, reporting standards, management certification and compliance requirements, most broker dealers trade stocks on the OTCQB. Historically this has resulted in greater liquidity and awareness for companies that reach the OTCQB tier.
Key elements and benefits of uplisting to the OTCQB include:
- Companies must remain current and compliant in their reporting to the SEC
- Minimum bid price test of $0.01 removes companies that are most likely to be the subject of dilutive stock fraud schemes and promotion
- Improved investor confidence through verified information, confirming that the Company Profile displayed on www.otcmarkets.com is current and complete
- Annual management certification process to verify officers, directors, controlling shareholders, and shares outstanding
- Greater information availability for investors through the OTC Disclosure & News Service
- Transparent prices for investors through full-depth of book with Real Time Level 2 quotes
“We anticipate that trading on the OTCQB will raise our visibility within the investment community and will help to broaden our shareholder base,” stated John Verghese, CTO & Director of Apotheca. “Uplisting to the OTCQB will be a significant milestone for the company (if our application is accepted by the OTCMARKETS) as it provides shareholders and potential investors with greater transparency and liquidity, and exposes Apotheca to institutional investors which do not invest in Pink Sheet companies.”
Apotheca Biosciences is at the forefront of medical technologies with the development of a CBD pain patch for the healthcare and consumer care industry. This acquisition will provide knowledge and expertise to the development of this CBD product, along with our other products. Our pipeline of products includes transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids.
Apotheca Biosciences is a pioneering biotech company with an emphasis in research and development in addition to the creation of high-grade nutraceuticals and cosmetics. The health of our customers takes precedence and our solid business strategy ensures focus on customer well-being. Our goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects our strategy and research. For more information on Apotheca Biosciences, please visit www.apothecabio.com
About Apotheca Biosciences Inc.
Apotheca is a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Its pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. Apotheca believes that it can deliver meaningful benefits using its technologies to the world’s aging population.
To request further information about Apotheca, please email info@apothecabio.com, or visit its website athttp://www.apothecabiosciences.com/, or visit it on FB @apotheca and Twitter @apotheca
Forward-Looking Statements
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.